Exchange: NASDAQ·Updated 07:41 PM EDT
ALLO logo

ALLO Allogene Therapeutics Inc

$2.17
$0.14
(6.90%)
Today
Closed $2.17
$0.0005
(0.02%)
After Hours
Reported EarningsAug 12
Mkt Cap$701.35M
Vol6.16M

About ALLO

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
53

Neutral Sentiment

How do you feel about ALLO?

Advertisement|Remove ads.